VRP Verona Pharma Plc

 
TIDMVRP 
 
   LONDON, April 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma" or the "Company"), a clinical-stage 
biopharmaceutical company focused on respiratory diseases, announces 
that it will host an investor and analyst R&D forum in London on 
Wednesday, May 8th from 8:30 a.m. BST to 11:30 a.m. BST. 
 
   The event will provide insights into the unmet medical need, the 
challenges of treating chronic obstructive pulmonary disease ("COPD") 
and the payer landscape.  Management will present an overview of COPD 
and of ensifentrine in late-stage clinical development for this 
indication. The forum will feature a panel of physicians and key opinion 
leaders in the field of COPD to provide a clinical perspective, as well 
as a patient living with COPD. 
 
   Attendance at this event is by invitation only.  For additional details, 
please contact Victoria Stewart at info@veronapharma.com.  A live 
webcast can be accessed on the Investor Relations section of the Verona 
Pharma website at http://investors.veronapharma.com. A webcast replay 
will be available for 30 days following the event. 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, ensifentrine (RPL554), is a first-in-class, 
inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that 
has been shown to act as both a bronchodilator and an anti-inflammatory 
agent in a single compound. Ensifentrine is currently in Phase 2b 
clinical development for the maintenance treatment of COPD and is 
planned to enter Phase 3 trials for this indication in 2020. Verona 
Pharma is also developing ensifentrine for the treatment of cystic 
fibrosis and asthma. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer       info@veronapharma.com 
Victoria Stewart, Director of Communications 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: +44 (0) 20 7710 7600 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
FTI Consulting (UK Media and Investor enquiries)   Tel: +44 (0)20 3727 1000 
Simon Conway / Natalie Garland-Collins             veronapharma@fticonsulting.com 
 
Westwicke, an ICR Company (US Media and Investor 
enquiries) 
Darcie Robinson                                    Tel: +1 203-919-7905 
                                                    Darcie.Robinson@icrinc.com 
Stephanie Carrington                               Tel. +1 646-277-1282 
                                                    Stephanie.Carrington@icrinc.com 
 
 
 
 
 

(END) Dow Jones Newswires

April 25, 2019 07:07 ET (11:07 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024

Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024